International Conference On OpioidsInternational Conference On Opioids
  • Home
  • Presentations
  • Posters
  • Info
    • ——————————
      • Call For Presentations, Posters, etc
      • CME Information
      • Sponsorship & Exhibits
    • ——————————
      • Opioid Safety Tips Project
      • Press & Media
        • Speakers
      • Lodging and hotels
    • ——————————
      • Conference Information
      • Terms and conditions
      • Tickets
      • Contact Us
    • ——————————
      • Conference Committee
      • Educational Support
      • Satellite Symposia
  • Register Now to Watch
  • Login
  • Home
  • Presentations
  • Posters
  • Info
    • ——————————
      • Call For Presentations, Posters, etc
      • CME Information
      • Sponsorship & Exhibits
    • ——————————
      • Opioid Safety Tips Project
      • Press & Media
        • Speakers
      • Lodging and hotels
    • ——————————
      • Conference Information
      • Terms and conditions
      • Tickets
      • Contact Us
    • ——————————
      • Conference Committee
      • Educational Support
      • Satellite Symposia
  • Register Now to Watch
  • Login
Presentations

Presentations

icoo.20.pp.0041_Langabeer Screen Shot

Assessing Prevalence of Co-Occurring Mental Health Disorders in Non-Fatal Overdose Survivors

https://opioidconference.org/wp-content/uploads/2020/08/Langabeer-ICOO-2020-Virtual-Final-Video.mp4

Assessing Prevalence of Co-Occurring Mental Health Disorders in Non-Fatal Overdose Survivors

James Langabeer, PhD; Tiffany Champagne-Langabeer, PhD; Christine Bakos-Block, PhD; Andrea Yatsco, PhD
University of Texas Health Science Center at Houston

While it known there is a moderate co-occurrence of both psychiatric and opioid use disorder (OUD) generally, it is not known whether this significantly differs in a high risk population of those with a recent overdose. In this research, we focus on identifying the prevalence of co-occurring disorders, specifically for those non-treatment seeking individuals who access emergency services for opioid overdose.

Read more
Screen Shot 2020-07-08 at 8.48.53 AM

Potentiating new Neurological pain drugs from cannabis (CBD/THC)

https://opioidconference.org/wp-content/uploads/2020/07/Potentiating-new-Neurological-pain-drugs-from-cannabis_720p_SeanHall.mp4

Potentiating new Neurological pain drugs from cannabis (CBD/THC)

Sean Hall, MD
MedLab Clinical Limited
Alexandria, Australia

In this presentation, Dr. Hall discusses active research  identifying new neurological drugs based on  cannabis, specifically CBD/THC derived products for use in pain management.

Neurology is a complex area, potentially requiring a combination of surgical and non-surgical intervention. Regardless of the intervention plan, Neurology is hindered with a number of co-morbidities that can diminish patient outcomes, one in particular is pain. Pain management requires a number of pharmaceutical agents principally from the opioid class of drugs, potentiating heightened secondary organ toxicity profiles. Further it is accepted that some 33% + of patients undergoing chemotherapy will state that their pain is under-managed. Cannabinoids potentiate new treatments in pain management and posit opioid reduction.

Handouts of Slides:

Coming Soon.

Read more
icoo.20.pp.0046_Kriegsman_Daley_Meuse

Outreach, Intervention and Care Coordination for Patients with Opioid Use Disorder

https://opioidconference.org/wp-content/uploads/2020/07/ICOO-3_2-Kriegman_Final_720P.mp4

Outreach, Intervention and Care Coordination for Patients with Opioid Use Disorder

Ari Kriegsman, MD; Erin Daley, RN, BSN; Carolyn Meuse, RN, BSN

We highlight one community hospital system’s efforts to combat the opioid crisis and help those most vulnerable to its effects. This includes street based outreach to engage those out of care, a hospital based addiction medicine service, residential treatment services, and care coordination to help navigate and give support throughout the continuum.

Presentation Handouts: icoo.20.pp.0046 3_2_KRIEGSMAN_DALEY_MEUSE_ICOO slide

Read more
icoo.20.pp.0091 Opioid Stewardship Across the Continuum of Care

Opioid Stewardship Across the Continuum of Care

https://opioidconference.org/wp-content/uploads/2020/11/ICOO-Virtual-McPherson-Mendoza-Uritzsky-720P-Coverted.mp4

Opioid Stewardship Across the Continuum of Care

Mary Lynn McPherson, PharmD, MA, MDE, BCPS; Tanya Uritsky, PharmD; Kelly Mendoza, MS, PharmD, BCPS

In the presentation “Opioid Stewardship Across the Continuum of Care”, Dr. McPherson, Dr. Uritsky and Dr. Mendoza describe ways to measure success in opioid stewardship across four practice arenas – outpatient, inpatient, palliative care, and hospice. Additionally, they discuss examples of best practices as part of opioid stewardship as well as recognizing/exposing the barriers to implementing opioid stewardship.

Handouts of Slides:

icoo.20.pp.0091 Opioid Stewardship Across the Continuum of Care Handouts

Read more
icoo.20.pp.0076_Langabeer Screen Shot

Preliminary Results from a Post-Overdose Outreach & Emergency Department-Initiated Opioid Initiative

https://opioidconference.org/wp-content/uploads/2020/11/icoo.20.pp_.0076-Langabeer-et-al_720p.mp4

Preliminary Results from a Post-Overdose Outreach & Emergency Department-Initiated Opioid Initiative

James Langabeer, PhD; Tiffany Champagne-Langabeer, PhD; Kimberly Chambers, MD
University of Texas Health Science Center at Houston

This study is funded by the Texas HHSC State Opioid Response Program, through SAMHSA. We know that treatment capacity alone is insufficient. We need better Coordination across medical, criminal justice, public health, and first responders. We may be at a critical juncture where patients are more ready and willing to engage in treatment.
Hypothesis: Immediate intervention, outreach, and comprehensive follow-up services initiated post-OD in the Emergency Department could be effective at improving engagement and retention in treatment. (Note: Please see a presentation from the same team located at: https://opioidconference.org/icoo-20-pp-0041/)

Presentation Slide Handouts: icoo.20.pp.0076 1_6_Intl Conf on Opioids Pres (Langabeers)

Read more
Koyyalagunta Screen Shot

Unique Challenges in Oncologic Pain Patients with Substance Use Disorders

https://opioidconference.org/wp-content/uploads/2020/10/icoo.20.pp_.0036_ICOO-Virtual-1_2_Koyyalagunta_Final_Conversion-720P.mp4

Unique Challenges in the Oncologic Pain Patients with Substance Use Disorders:
Scope of the Problem

Dhanalakshmi Koyyalagunta, MD; Joseph Arthur, MD; Larry Driver, MD

In this presentation, Dr. Koyyalagunta, Dr. Arthur and Dr. Driver explore the myriad unique challenges dealing with oncology patients with comorbid substance use disorders

Presentation Handouts:

icoo.20.pp.0036 1_2_1_KOYYALAGUNTA_ICOO 2019-LK_Slides

icoo.20.pp.0036 1_2_2_ARTHUR_ICOO 6.9.19_V2_slides

Read more
icoo.20.pp.0111_Clinical pearls of pharmacogenomics_Screen Shot

Clinical Pearls of Pharmacogenomics

https://opioidconference.org/wp-content/uploads/2020/06/icoo.20.pp_.0111_GMT20201101-164449_ICOO-Run-T_1920x1080.mp4

Clinical Pearls of Pharmacogenomics

Jeffrey Bettinger, PharmD, Pain Management Clinical Pharmacist, Saratoga Hospital Medical Group, Saratoga Springs, NY
Jacqueline Cleary, PharmD, BCACP, Assistant Professor of Pharmacy Practice, Albany College of Pharmacy and Health Sciences, Albany, NY

The presentation will focus on the role of pharmacogenomic testing and result application in the setting of both acute and chronic pain management. Several pharmacodynamic and kinetic genes will be discussed as useful tools to better manage targeted pain therapies.

The field of pharmacogenomics is often viewed as the new frontier in pharmacology, as it quite literally combines pharmacology (the science of drugs) with genomics (the study of genes). Throughout the latter part of 21st century, research has continued to expand within this field not only in supporting the current use of pharmacogenomic testing in a variety of specialty areas, but identifying multiple genetic variants that can make an instrumental difference when managing pain.

Presentation Slide Handouts: icoo.20.pp.0111_Clinical pearls of pharmacogenomics – ICOO 2020 Handouts

Read more
icoo.20.pp.0101-Cannabinoids

Cannibinoids: All the Rage, But Are They Safe and Effective?

https://opioidconference.org/wp-content/uploads/2020/11/icoo.20.pp_.0101-Haley-Busch-ICOO-2020-Virtual-1080P.mp4

Cannibinoids: All the Rage, But Are They Safe and Effective?

Haley Busch, PharmD, BCPS
Clinical Pharmacist Specialist – Opioid Stewardship
CHI Saint Joseph Health

In this presentation, Dr. Busch discusses the legal status of cannabis and cannabis derived products for use in pain management. Additionally Dr. Busch presents the current literature available for potential utlization of cannabidiol in medical practice as well as reviewing the FDA approved cannabis-derived products and respective indications.

Handouts of Slides:

Coming Soon.

Read more
icoo.20.pp.0029_Barrett_2020_Sept_Presentation_EDandOpioids_Handouts

To Save A Life: Emergency Medicine And The Opioid Epidemic

https://opioidconference.org/wp-content/uploads/2020/09/icoo.20.pp_.0026_Barrett_zoom_5.mp4

TO SAVE A LIFE: EMERGENCY MEDICINE AND THE OPIOID EPIDEMIC

Tyler W. Barrett, MD MSCI FACEP FHRS, Associate Professor, Medical Director, Department of Emergency Medicine
Vanderbilt University Medical Center, Nashville, TN

Presentation Handouts: icoo.20.pp.0027_Barrett_2020_Sept_Presentation_EDandOpioids

Read more
icoo.20.pp.0021 OIC Screen Shot

Opioid Induced Constipation in Chronic Pain

https://opioidconference.org/wp-content/uploads/2020/11/icoo.20.pp_.0021-OPIOIDS-INDUCED-CONSTIPATION-Guadix-Granada-SPAIN-Converted.mp4

Opioid Induced Constipation in Chronic Pain

Velazquez Rivera, I.
Sanchez Del Aguila, M.
Garcia Velasco, M.P.

Unidad Del Dolor
Hospital De Alta Resolucion De Guadix, Spain

In this presentation, a Spanish team presents their latest findings on the management of opioid induced constipation for patients on opioid therapies.

Slide Handouts: icoo.20.pp.0021 opioid induced constipation – Guadix, Granada – SPAIN HANDOUT

Read more
Search
Latest Presentations
  • Clinical Pearls of Pharmacogenomics December 23, 2020
  • Relapses during addiction treatment found after a change in urine drug testing methodologies November 17, 2020
  • Preliminary Results from a Post-Overdose Outreach & Emergency Department-Initiated Opioid Initiative November 12, 2020
  • Opioid Induced Constipation in Chronic Pain November 9, 2020
Categories
  • Posters
  • Presentations

The 2020 International Conference on Opioids (ICOO 2020) has assembled the best and brightest minds in opioid analgesics who will explore the challenges of using opioids to treat pain.

The International Conference On Opioids is dedicated to presenting the latest research and practice for managing patients on opioid therapies. The conference addresses all aspects of opioids in medicine and the public health.

INFORMATION
  • Terms and conditions
  • Privacy Statement
NEWSLETTER


    Contact Us
    info@opioidconference.org
    Copyright 2020 Weston Medical Publishing, LLC - All Rights Reserved | Website Design By - T3kniq
    This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Cookie settingsACCEPT
    Privacy & Cookies Policy

    Privacy Overview

    Privacy Statement


    Privacy and User Data Policy

    GDPR Update:

    The data collected from registered and non-registered users of this journal falls within the scope of the standard functioning of peer-reviewed journals. It includes information that makes communication possible for the editorial process; it is used to informs readers about the authorship and editing of content; it enables collecting aggregated data on readership behaviors, as well as tracking geopolitical and social elements of scholarly communication.

    This journal’s editorial team uses this data to guide its work in publishing and improving this journal. Data that will assist in developing this publishing platform may be shared with its developer Public Knowledge Project in an anonymized and aggregated form, with appropriate exceptions such as article metrics. The data will not be sold by this journal or PKP nor will it be used for purposes other than those stated here. The authors published in this journal are responsible for the human subject data that figures in the research reported here.

    Those involved in editing this journal seek to be compliant with industry standards for data privacy, including the European Union’s General Data Protection Regulation (GDPR) provision for “data subject rights” that include (a) breach notification; (b) right of access; (c) the right to be forgotten; (d) data portability; and (e) privacy by design. The GDPR also allows for the recognition of “the public interest in the availability of the data,” which has a particular saliency for those involved in maintaining, with the greatest integrity possible, the public record of scholarly publishing.

    Requests per item (a) through (e) above should be sent to the journal's mailbox, jom(at)pnpco.com

    The names and email addresses entered in this journal site will be used exclusively for the stated purposes of this journal and will not be made available for any other purpose or to any other party.

    What Data does this Website Process?

    The system, based the PKP Open Journal System applications, process personal data as a fundamental part of their operations. Most data is only provided by consent, ie. through manual user registration, though some visitation data (eg. cookies, usage logs) may also be recorded.

    User Registration Data

    When a visitor creates a user account in a PKP application, the following personal information is processed and stored (with some minor variation between OMP and OJS, and from version to version):

    ●   Salutation

    ●   First name*

    ●   Middle name

    ●   Last name*

    ●   Suffix

    ●   Username

    ●   Gender

    ●   Password (encrypted)

    ●   Email address*

    ●   ORCiD ID

    ●   Website

    ●   Mailing Address

    ●   Country

    ●   Phone

    ●   Fax

    ●   Affiliation

    ●   Biography

    ●   Registration date

    ●   Last login date

    ●   Locales

    ●   Reviewing interests

    ●   Role registrations (author, reader, and/or reviewer)

    Only the username, first name, last name, email and password fields are required.

    Storage

    This information is stored in the application database. Only the user password

    is encrypted.

    Availability and Access

    This information is available to the user via their User Profile (and, with the exception of the username and dates, can be edited). System administrators, journal managers, and editors can also access and edit this data (except the username and dates) via the application back end. The data can be downloaded by journal managers in XML format. The data is not otherwise publicly available.

    Erasure

    This data can be erased by the journal manager using the Merge Users tool, without affecting any editorial records. The erasure is subject to the considerations raised in the section “Scholarly Publishing, Data Privacy, and the Public Interest”, above.

    Contributor Metadata Information

    When a manuscript is submitted to a PKP application, contributor information is included. Contributors can be authors, translators, volume editors, and so on. This information is stored as submission metadata and is provided as part of any published manuscript record. The following contributor information is collected:

    ●   Salutation

    ●   First name*

    ●   Middle name

    ●   Last name*

    ●   Email address*

    ●   Suffix

    ●   ORCiD ID

    ●   Website

    ●   Country*

    ●   Affiliation

    ●   Biography

    Only the first name, last name, email address and country fields are required.

    Storage

    This information is stored in the application database.

    Data Transfer

    We do not sell or transfer to third parties user information from this system.

    General Visitor Information

    PKP applications also collect general visitor usage data, including:

    ● Cookie information, to manage session history. Cookies are required to maintain a login session in PKP applications.

    ● Optionally, detailed usage log data, including: IP address; pages visited; date visited; and browser information, in application log files, as part of the Usage Statistics plugin. An anonymization option is available to privatize this information.

    ● Optionally, country, region and city information, in the metrics database. This data collection requires additional setup and is not enabled by default.

    Other data may be tracked, either on the server or via third parties:

    ● Script loads from CDN servers;

    ● IP address information (including date, browser, etc.) in web server logs (separate from application log files as part of the Usage Statistics plugin).

    Detailed instructions in limiting the amount of data you collect, and providing consent for the data you collect, can be found below.

    Storage

    ● Cookies: A cookie (usually titled “OJSSID” or “OMPSID”) is created when first visiting a PKP application and is stored on the visitor’s computer. It is only used to store a session ID, and to facilitate logins. (If the visitor blocks cookies, OJS will still work properly, though they will not be able to log in.)

    ● Usage Statistics log files: As part of the usage statistics framework and plugin, OJS may store detailed application log files in the submission files directory (configured as the files_dir parameter in the OJS config.inc.php file), in a “usageStats” directory.

    ● Geographical data: Filtered usage data, including possibly geographic data, is also stored in the OJS database, in a “metrics” table.

    Availability and Access

    ● Cookies: These are available via the visitor’s browser settings.

    ● Usage Statistics log files: Only individuals with server file access can access application log files.

    ● Geographical data: Journal Managers can access filtered usage data by using the OJS usage report plugins.

    Erasure

    ● Cookies: These can be deleted via the visitor browser.

    ● Usage Statistics log files: These can be erased by system administrators with file access.

    ● Geographical data: This can only be erased by deleting records from the database directly, which also typically requires system administrator access.

    Portions of this privacy statement are copyright by Simon Fraiser University Licensed wth CC4.0-BY.
    Necessary
    Always Enabled

    Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.

    Non-necessary

    Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.